www.fda.gov/medical-devices/safety-communications/ fda-warns-biotin-may-interfere-lab-tests-fda-safety-communi cation; 2017. Accessed June 30, 2020. 4. Chang MJ, Lipner SR. Altmetric analysis of biotin in scholarly outputs after the biotin Food and Drug Administration warning.

Background In South Korea, there have been few nationwide epidemiologic studies about premalignant actinic keratosis (AK), squamous cell carcinoma in situ (Bowen’s disease), nonmelanoma skin cancer (NMSC), malignant melanoma of the skin (MM), Kaposi’s sarcoma (KS), connective and soft tissue cancers, or mycosis fungoides (MF). Objective Using a nationwide population-based study, we attempted to measure the incidence and the prevalence of the above-mentioned tumors in South Korea. Methods The database we used included all claims in the Korean National Health Insurance program and the Korean Medical Aid program from 2008 to 2016. The International Classification of Diseases, 10th revision (ICD-10) was used to record diagnoses in this database. This data included AK, Bowen’s disease, NMSC, MM, KS, connective and soft tissue cancers, and MF. Results The age-standardized incidence and prevalence rate of AK, Bowen’s disease, NMSC, MM, KS, connective and soft tissue cancers, as well as MF increased during the periods we investigated. The incidence and prevalence rate of AK and NMSC have increased two- to three-fold. In the case of Bowen’s disease, MM, KS, connective and soft tissue cancers, or MF, we observed no significant tendency in age-standardized incidence or prevalence. Conclusion We confirmed that the age-standardized incidence and prevalence rates of NMSC and AK tended to increase. These results might contribute to developing preventive and therapeutic strategies for skin cancers and may become a source for further studies.

Background/purpose Ultraviolet B (UVB) laser irradiation in a targeted manner is a reasonable treatment option for localized vitiligo. Recently, narrow‐band UVB gain‐switched 311‐nm titanium:sapphire lasers (TSL) were developed for the treatment of localized vitiligo. We aimed to compare efficacy, patient satisfaction, and safety between the conventional 308‐nm excimer laser (EL) and gain‐switched 311‐nm TSL in patients with vitiligo. Methods The 13‐paired lesions from 10 patients who had small vitiligo patches were included in this prospective intra‐patient comparison trial. Each pair was randomly assigned to each laser treatment group and treated twice weekly for 12 weeks. The global photographic assessments by dermatologists, objective numerical assessments by imaging analyzer, and patient's satisfaction were used to evaluate the effectiveness. Adverse effects were also investigated at every visit. Results All treated lesions showed improvement of about 50% after 12 weeks. There was no significant difference between EL‐ and TSL‐treated groups. Patient satisfaction and preference among the groups were also similar. Regarding safety, there were no serious adverse effects requiring cessation of the treatments; however, the severity score for persistent erythema (lasting >24 hours) was significantly lower in the TSL group than in the EL group. Conclusions The gain‐switched 311‐nm TSL exhibited similar efficacy to the 308‐nm EL in treating vitiligo as well as improved safety. Therefore, the 311‐nm TSL is considered as a candidate device to replace the EL as a new and promising treatment option for localized vitiligo.

No abstract

No abstract